Drug

Anti-CD20 Monoclonal Antibody MIL62 clinical trials

Also written MIL62.

studies test it: 10
open now: 3
in phase 3: 3
first study started: 2017

Keep track of what changes. Save the Anti-CD20 Monoclonal Antibody MIL62 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Recombinant Humanized Monoclonal Antibody MIL62 Injection: 4

Development codes

MIL62: 7

Studies by the year they started

10 studies that test it; most in 2022 (2)

Studies that test Anti-CD20 Monoclonal Antibody MIL62, by start year
Year	Studies
2017	1
2019	1
2020	1
2021	1
2022	2
2023	2
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 5
Phase 2: 6
Phase 3: 3

What it is tested for

Each study’s main condition, where its own words name it.

Lupus Erythematosus, Systemic: 2
Lymphoma, B-Cell: 2
Neuromyelitis Optica: 1
Lupus Nephritis: 1
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: 1
Lymphoma, Follicular: 1

Who runs them

Industry 9 · Other 1

Beijing Mabworks Biotech Co., Ltd. (8) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Chinese PLA General Hospital (1)

Often tested with

Tested in the same studies.

Orelabrutinib (1) · Lenalidomide (1)

Studies

Open first, then newest update. How each study uses Anti-CD20 Monoclonal Antibody MIL62 is read from its arms, and is right about nine times in ten.